Shiga toxin-associated hemolytic uremic syndrome: Advances in pathogenesis and therapeutics

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 4, 2012, Pages 433-440

  Petruzziello Pellegrini, Tania N ^a,b   Marsden, Philip A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

complement pathway; CXCR4; hemolytic uremic syndrome; SDF 1; Shiga toxin; Shiga toxin producing E. coli

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SHIGA TOXIN; SORBITOL; STROMAL CELL DERIVED FACTOR 1;

BACTERIAL GENE; BLOODY DIARRHEA; COMPLEMENT ACTIVATION; DIARRHEA; ENDOCYTOSIS; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI O104; FERMENTATION; GENE EXPRESSION; GENE TRANSFER; HEMOLYTIC UREMIC SYNDROME; INCIDENCE; INCUBATION TIME; INTRACELLULAR TRANSPORT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RESERVOIR; REVIEW; SEROTYPE; THROMBOSIS; ZOONOSIS;

ANIMALS; CHEMOKINE CXCL12; COMPLEMENT ACTIVATION; DIARRHEA; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PHENOTYPE; RECEPTORS, CXCR4; SHIGA TOXINS; SHIGA-TOXIGENIC ESCHERICHIA COLI; SIGNAL TRANSDUCTION;

EID: 84862142302     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328354a62e     Document Type: Review

References (47)

1. Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012; 217:235-243.
2. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676-1687.
3. Karmali MA, Gannon V, Sargeant JM. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 2010; 140:360-370.
4. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-1086. (Pubitemid 40386785)
5. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010; 2:2769-2794.
6. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25: 2231-2240.
7. Jansen A, Kielstein JT. The new face of enterohaemorrhagic Escherichia coli infections. Euro Surveill 2011; 16.
8. Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011; 2011:908407.
9. Rasko DA, Webster DR, Sahl JW, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365:709-717.
10. Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl 2009; 75:S17-S19.
11. Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function-where membrane structure and pathology intersect. FEBS Lett 2010; 584:1879-1886.
12. Endo Y, Tsurugi K, Yutsudo T, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171:45-50. (Pubitemid 18042873)
13. Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998; 101:372-382. (Pubitemid 28067334)
14. Petruzziello-Pellegrini TN, Yuen DA, Page AV, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 2012; 122:759-776.
15. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolyticuraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1:619-620. (Pubitemid 13152343)
16. Johannes L, Romer W. Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8:105-116.
17. Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365:1763-1770.
18. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771-1780.
19. Report: Final presentation and evaluation of epidemiological findings in the EHEC O104:H4 outbreak. Berlin: Robert Koch Institute; 2011.
20. The German EHEC-HUS Registry. The German 2011 epidemic of Shiga toxin-producing E. Coli-the nephrological view. Nephrol Dial Transplant 2011; 26:2723-2726.
21. Rohde H, Qin J, Cui Y, et al. Open-source genomic analysis of Shiga-toxinproducing E. coli O104:H4. N Engl J Med 2011; 365:718-724.
22. Mellmann A, Harmsen D, Cummings CA, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One 2011; 6:e22751.
23. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11:671-676.
24. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010; 8:26-38.
25. Scheutz F, Nielsen EM, Frimodt-Moller J, et al. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. Euro Surveill 2011; 16:pii-19889.
26. Wieler LH, Semmler T, Eichhorn I, et al. No evidence of the Shiga toxinproducing E. coli O104:H4 outbreak strain or enteroaggregative E. coli (EAEC) found in cattle faeces in northern Germany, the hotspot of the 2011 HUS outbreak area. Gut Pathog 2011; 3:17.
27. European Centre for Disease Prevention and Control and European Food Safety Authority. Shiga toxin/verotoxin-producing Escherichia coli in humans, food and animals in the EU/EEA, with special reference to the German outbreak strain STEC O104. Stockholm: ECDC; 2011.
28. Scavia G, Morabito S, Tozzoli R, et al. Similarity of Shiga toxin-producing Escherichia coli O104:H4 strains from Italy and Germany. Emerg Infect Dis 2011; 17:1957-1958.
29. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089-1093.
30. Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 2010; 19:242-247.
31. Thurman JM, Marians R, Emlen W, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1920-1924.
32. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394-6400.
33. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187:172-180.
34. Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503-5513.
35. Herper M. The world's most expensive drugs. Forbes; 2010.
36. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561-2563.
37. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378:1166-1173.
38. Garg AX, Clark WF, Salvadori M, et al. Microalbuminuria three years after recovery from Escherichia coli O157 hemolytic uremic syndrome due to municipal water contamination. Kidney Int 2005; 67:1476-1482. (Pubitemid 40463124)
39. Kim JJ. Immunoadsorption for haemolytic uraemic syndrome. Lancet 2011; 378:1120-1122.
40. Tsai M, Kita A, Leach J, et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest 2012; 122:408-418.
41. Mukhopadhyay S, Linstedt AD. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012; 335:332-335.
42. Matouk CC, Marsden PA. Molecular insights into the thrombotic microangiopathies. In: Mount DB, Pollack MR, editors. Molecular and genetic basis of renal disease: a companion to Brenner Rector's the kidney. Philadelphia: Saunders; 2008. pp. 453-480.
43. Takabatake Y, Sugiyama T, Kohara H, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 2009; 20:1714-1723.
44. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393:591-594. (Pubitemid 28319250)
45. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-864. (Pubitemid 39070860)
46. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4 + hemangiocytes. Nat Med 2006; 12:557-567.
47. Ding M, Cui S, Li C, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006; 12:1081-1087. (Pubitemid 44353390)